RT Journal Article
T1 Antibody engineering: facing new challenges in cancer therapy
A1 Sanz, Laura
A1 Cuesta Martínez, Ángel
A1 Compte, Marta
A1 Álvarez Vallina, Luis
AB Antibody-based therapeutics are beginning to realize the promise enclosed in their early denomination as magic bullets. Initial disappointment has turned into clinical and commercial success, and engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials. Recent structural and functional data have allowed the design of a new generation of therapeutic antibodies, with strategies ranging from complement-mediated and antibody-dependant cellular cytotoxicity enhancement to improved cytotoxic payloads using toxins, drugs, radionucleids and viral delivery. This review considers the structure of different types of recombinant antibodies, their mechanism of action and how their efficacy has been increased using a broad array of approaches. We will also focus on the additional benefits offered by the use of gene therapy methods for the in vivo production of therapeutic antibodies.
PB Nature
SN 1671-4083
SN 1745-7254
YR 2005
FD 2005-06
LK https://hdl.handle.net/20.500.14352/114669
UL https://hdl.handle.net/20.500.14352/114669
LA eng
NO Sanz L, Cuesta ÁM, Compte M, Álvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacologica Sinica [Internet]. junio de 2005 [citado 16 de enero de 2025];26(6):641-8. Disponible en: https://www.nature.com/doifinder/10.1111/j.1745-7254.2005.00135.x
NO Fondo de Investigación Sanitaria
NO Comunidad Autónoma de Madrid
NO European Commission-ERC
DS Docta Complutense
RD 28 abr 2025